TWD 179.0
(-1.65%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.74 Billion TWD | -20.3% |
2022 | 2.18 Billion TWD | 8.39% |
2021 | 2.01 Billion TWD | 45.16% |
2020 | 1.38 Billion TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 1.96 Billion TWD | 12.8% |
2024 Q2 | 1.97 Billion TWD | 0.66% |
2023 Q4 | 1.74 Billion TWD | 1.7% |
2023 FY | 1.74 Billion TWD | -20.3% |
2023 Q1 | 2.2 Billion TWD | 0.77% |
2023 Q3 | 1.71 Billion TWD | -19.73% |
2023 Q2 | 2.13 Billion TWD | -3.12% |
2022 Q4 | 2.18 Billion TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 1.47 Billion TWD | -17.746% |
Maxigen Biotech Inc. | 131.88 Million TWD | -1220.52% |
SciVision Biotech Inc. | 533.66 Million TWD | -226.336% |
Bionime Corporation | 3.3 Billion TWD | 47.344% |
Pegavision Corporation | 3.87 Billion TWD | 55.096% |